First Administration of Leqembi for Alzheimer's Patients in Sweden Marks a New Era in Treatment
BioArctic Introduces Leqembi in Sweden
In a significant advancement for Alzheimer's disease treatment, BioArctic AB has announced that its pioneering drug Leqembi® (lecanemab) is now available for patients at a private clinic in Sweden. This marks the first instance where a patient has received treatment with Leqembi outside of a clinical study, following the EU approval granted in April 2025.
Gunilla Osswald, CEO of BioArctic, expressed her satisfaction, stating, "I am very happy that we are now starting to help people diagnosed with early Alzheimer's disease in Sweden as well. There is a significant unmet need for new treatment options that slow the progression of Alzheimer's disease..." Her remarks emphasize the urgency and importance of introducing effective treatments to mitigate the impact of Alzheimer's on patients and their caregivers.
The Journey of Leqembi
Leqembi, which targets the biological underpinnings of Alzheimer's, was specifically approved for adults diagnosed with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s Disease who carry certain genetic profiles. Following its EU endorsement, efforts were made in Sweden for patient accessibility. However, the road has not been without obstacles. A negative recommendation from the New Therapies Council (NT-rådet) in April 2026 regarding the inclusion of Leqembi in public health funding led the Executive Health in Stockholm to step in and offer the treatment on a private basis.
The approval of Leqembi is the culmination of over two decades of research spearheaded by Professor Lars Lannfelt from Uppsala University. As the drug became commercially available, it represented not only a scientific breakthrough but also a promising beacon of hope for individuals grappling with early stages of Alzheimer’s disease.
Development Background
BioArctic has been involved in a long-standing alliance with Eisai, the company responsible for global commercialization and regulatory approval of Leqembi. The collaboration has fostered the growth of innovative treatments for Alzheimer’s, with lecanemab being recognized as the first therapy targeting the fundamental causes of the disease. It’s noteworthy that BioArctic has secured rights to commercialize Leqembi in the Nordic region together with Eisai, without incurring development costs.
In essence, Leqembi is a humanized monoclonal antibody that combats amyloid-beta aggregates, a key component implicated in Alzheimer’s pathology. The drug is already approved in 53 countries and has undergone rigorous clinical trials to validate its effectiveness and safety.
Clinical Implications and Broader Impact
Leqembi's introduction heralds a new chapter not only for Swedish patients but also for the global fight against Alzheimer’s disease. Currently administered through a treatment regimen that involves two-week hospital visits for the first 18 months, followed by monthly doses, it’s crucial for healthcare providers to understand the patient population eligible for this treatment.
With ongoing studies like AHEAD 3-45 targeting preclinical Alzheimer's and others assessing the long-term effects of lecanemab, the commitment to addressing Alzheimer's with scientifically grounded solutions remains steadfast. The collaboration between BioArctic and Eisai continues to thrive, with efforts aimed at developing additional therapies and ensuring effective patient care, ultimately transforming the landscape of Alzheimer’s treatment.
Conclusion
As Sweden witnesses the inaugural treatment with Leqembi, the journey underscores the relentless pursuit of medical advancements in neurodegenerative diseases. BioArctic's dedication, combined with its strategic partnerships, not only enhances the prospects for Alzheimer’s treatments but also offers a hopeful narrative for families navigating the challenges of this debilitating condition. The battle against Alzheimer’s disease is far from over, but with innovations like Leqembi entering the sphere, there is a renewed spirit of optimism for patients and caregivers alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.